Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Adaptive Biotechnologies Corp

NASDAQ: ADPT · Life Sciences · 17 alerts · CIK 1478320

Share price
$27.87Close, Nov 16
Market cap
$4.51B
Shares outstanding
161.88MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Adaptive Biotechnologies Corp filings on SEC EDGAR ↗

4:33 PM ET 10-Q
Financial Results

Adaptive Biotechnologies Q3 2026 Results: Net Income $2.88M, Down 69.9% YoY

Adaptive Biotechnologies reported a net loss of $57.2 million for the first nine months of 2026, compared to a $45.9 million loss in the prior year period, impacted by a $23.7 million loss on revenue interest liability extinguishment. Despite the year-to-date loss, the company achieved a quarterly net income of $2.9 million in Q3 2026, though revenue for the quarter decreased to $83.9 million from $94.0 million year-over-year.

Key figure
Net income $2.88M · -69.9% YoY
4:16 PM ET 8-K
Financial Results

Adaptive Biotechnologies Financial Results

Adaptive Biotechnologies reported Q3 2026 financial results, achieving total company profitability ahead of expectations with $83.9 million in revenue and $2.8 million in net income. The company saw 44% growth in core MRD revenue (excluding milestones) and increased its full-year 2026 MRD revenue guidance. Management highlighted momentum in clonoSEQ testing and updated clinical guidelines for multiple myeloma as key growth drivers.

Term
Q3 2026

“Adaptive achieved total company profitability ahead of expectations in Q3 and delivered 44% growth in core MRD revenue. This momentum supports another increase in our full year outlook. Updated guidelines and a new definition of cure for multiple myeloma amplify the need for MRD testing and bolster clonoSEQ’s long-term potential.”

Chad Robins, chief executive officer and co-founder of Adaptive Biotechnologies

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.